pramipexole tablet
sivem pharmaceuticals ulc - pramipexole dihydrochloride monohydrate - tablet - 1mg - pramipexole dihydrochloride monohydrate 1mg - nonergot-derivative dopamine receptor agonists
pramipexole tablet
pro doc limitee - pramipexole dihydrochloride monohydrate - tablet - 1mg - pramipexole dihydrochloride monohydrate 1mg - nonergot-derivative dopamine receptor agonists
pramipexole dihydrochloride tablet
major pharmaceuticals - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride tablets are indicated for the treatment of parkinson's disease. pramipexole dihydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). none. risk summary there are no adequate data on the developmental risk associated with the use of pramipexole dihydrochloride tablets in pregnant women. no adverse developmental effects were observed in animal studies in which pramipexole was administered to rabbits during pregnancy. effects on embryofetal development could not be adequately assessed in pregnant rats; however, postnatal growth was inhibited at clinically relevant exposures [see data]. in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data oral administration of pramipexo
pramipexole dihydrochloride tablet
american health packaging - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride tablets are indicated for the treatment of parkinson's disease. pramipexole dihydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). none. risk summary there are no adequate data on the developmental risk associated with the use of pramipexole dihydrochloride tablets in pregnant women. no adverse developmental effects were observed in animal studies in which pramipexole was administered to rabbits during pregnancy. effects on embryofetal development could not be adequately assessed in pregnant rats; however, postnatal growth was inhibited at clinically relevant exposures [see data]. in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data oral administration of pramipexo
pramipexole ch pramipexole dihydrochloride monohydrate 1.5 mg tablet blister pack
southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate -
pramipexole ch pramipexole dihydrochloride monohydrate 0.5 mg tablet blister pack
southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate -
pramipexole scp pramipexole dihydrochloride monohydrate 1.5 mg tablet blister pack
southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.
pramipexole scp pramipexole dihydrochloride monohydrate 0.5 mg tablet blister pack
southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.5 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.
pramipexole scp pramipexole dihydrochloride monohydrate 0.25 mg tablet blister pack
southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.25 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. the symptomatic treatment of primary restless legs syndrome.
pramipexole scp pramipexole dihydrochloride monohydrate 0.125 mg tablet blister pack
southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.125 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. the symptomatic treatment of primary restless legs syndrome.